Details for Patent: 10,842,777
Which drugs does patent 10,842,777 protect, and when does it expire?
Patent 10,842,777 protects ATTRUBY and is included in one NDA.
This patent has twenty-three patent family members in eighteen countries.
Summary for Patent: 10,842,777
| Title: | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Isabella A. Graef, Mamoun M. Alhamadsheh | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Leland Stanford Junior University | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US16/510,574 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 10,842,777: Claim Scope, TTR Stabilizer Coverage, and Patent LandscapeU.S. Patent No. 10,842,777 protects three related method categories involving a defined Compound VIIa genus: TTR stabilization, reduction of amyloid fibril formation, and labeled-compound assays for detecting or quantifying transthyretin. The claims are composition-specific through the Compound VIIa structure and substituent Ra, but method-limited rather than directed to the compound as a standalone composition. The strongest commercial risk is for products that use Compound VIIc, or a pharmaceutically acceptable salt of Compound VIIc, in TTR-stabilization or amyloid-formation assays. The patent does not, based on the supplied claims, broadly cover every TTR stabilizer, every amyloid-treatment method, or every diagnostic assay involving TTR. What does U.S. Patent 10,842,777 cover?The patent contains three independent claim concepts:
Claims 2, 3, 5, 6, 8 and 9 narrow the independent claims by limiting the Ra substituent or requiring Compound VIIc. The patent therefore has a split claim strategy:
What chemical genus does Compound VIIa cover?Ra substituent scopeClaims 1, 4 and 7 define Compound VIIa by permitting Ra to be:
R6 is straight- or branched-chain alkyl containing one to three carbon atoms. The R6 options include methyl, ethyl, n-propyl and isopropyl groups, subject to the claim language and the structure shown in the patent. Claims 2, 5 and 8 remove the OH and CHO alternatives and retain the more polar carboxylic acid, amide, hydroxamic acid, ester and alkylamide substituents. This creates two practical tiers:
The exact chemical boundaries depend on the structural drawings and specification definitions for Compound VIIa and VIIc. The text supplied does not reproduce those structures. As a result, the exact molecular identity of Compound VIIc cannot be determined from the claim text alone. What does the pharmaceutically acceptable salt language add?The phrase "or a pharmaceutically acceptable salt thereof" extends the claims beyond the neutral form of the claimed compound. Depending on the compound’s ionizable groups, this may cover salts formed at a carboxylic acid or other relevant functional group. The salt language is important for commercial products because a development candidate may be formulated as a sodium, potassium, calcium, meglumine, lysine or other salt without changing the core active moiety. Infringement would turn on whether the salt is within the claim and whether the accused activity practices every method limitation. The claims do not expressly recite:
Those omissions make the claims potentially broad as methods, but they also create validity and infringement issues concerning enablement, written description, claim construction and the meaning of "contacting." How do claims 1 through 6 protect TTR stabilization and amyloid reduction?Claim 1: TTR stabilizationClaim 1 requires:
The claim does not require a particular measured stabilization endpoint. The supplied text also does not require that TTR remain tetrameric for a stated period or that a specific assay be used. Potentially relevant activities include:
The absence of a patient or disease limitation gives claim 1 broader potential reach than a conventional treatment claim. Its weakness is that the claim may depend heavily on how the court interprets the physical act of "contacting" and the required proof of TTR stabilization. Claim 2: narrowed Ra groupClaim 2 excludes the OH and CHO embodiments. A product using a carboxylic acid, amide, hydroxamic acid, ester or short-chain alkylamide remains within the literal scope if the rest of Compound VIIa is unchanged. Claim 3: Compound VIIc speciesClaim 3 narrows claim 1 to Compound VIIc or a pharmaceutically acceptable salt. A specifically identified clinical or research compound may therefore face greater risk under claim 3 than under the broader genus if it is structurally identical to VIIc. Claim 4: reduction of amyloid fibril formationClaim 4 uses the same Compound VIIa genus but changes the functional result from TTR stabilization to decreasing amyloid fibril formation. This creates separate infringement exposure. A defendant could avoid a claim 1 theory by disputing whether its product stabilizes TTR, but still face claim 4 if its product is shown to reduce fibril formation in the relevant tissue or fluid. The claim does not expressly limit fibrils to TTR-derived fibrils in the text supplied. The surrounding specification, however, is likely important because the claim is tied to TTR chemistry and Compound VIIa. The scope should not automatically be read as covering fibrils from unrelated proteins. Claims 5 and 6Claims 5 and 6 repeat the narrower Ra group and Compound VIIc limitation for claim 4. They provide fallback positions if the broader genus claims are challenged. What does claim 7 protect in TTR diagnostic testing?Claim 7 is technically distinct from claims 1 and 4. It requires:
This is a binding-proximity assay. The claim appears directed to a FRET-like or related energy-transfer method in which two binding events report on the conformation, assembly or occupancy state of the TTR tetramer. What is the significance of the orthogonal binding surface?TTR has thyroxine-binding pockets and additional ligand or antibody interaction surfaces. Claim 7 requires the second labeled species to bind at an orthogonal surface rather than simply measuring signal from the T4 pocket alone. That limitation may distinguish the claimed assay from:
The claim may cover measurement of TTR concentration, conformational state, ligand occupancy or tetramer assembly if the required energy-transfer relationship is present. It does not necessarily cover a diagnostic kit unless the kit is used in the claimed method. Claims 8 and 9Claim 8 narrows claim 7 to the carboxylic acid, amide, hydroxamic acid, ester and short-chain alkylamide Ra group. Claim 9 narrows claim 7 to Compound VIIc. This is likely the most commercially relevant diagnostic claim if VIIc is used as the labeled T4-pocket ligand. How many patents cover Compound VIIa and Compound VIIc?The supplied material establishes one patent, U.S. Patent No. 10,842,777. It does not establish the full patent family, continuation applications, foreign counterparts, terminal disclaimers, reexaminations or later patents claiming the same compounds. For freedom-to-operate purposes, the relevant estate should be separated into five categories:
U.S. Patent 10,842,777, based on the supplied claims, is principally a method patent. It does not show a standalone composition claim to Compound VIIa or VIIc. A product could therefore avoid the patent only if it does not practice the claimed methods, even if the underlying compound is chemically similar. That conclusion cannot be extended to other family members without reviewing the related applications. When does U.S. Patent 10,842,777 lose exclusivity?The patent issued on November 24, 2020. Its effective expiration depends on the earliest effective nonprovisional filing date, any patent-term adjustment, patent-term extension and terminal disclaimer. Patent term is generally measured from the earliest effective U.S. nonprovisional filing date for the relevant family, not from the issue date.[1] The supplied claim text does not establish the priority chain or the final term-adjustment calculation. The issue date alone is insufficient to state a legally reliable expiration date. Any commercial exclusivity analysis should use the USPTO patent record and the patent face data rather than infer expiration from the grant date. The patent is not, based on the claims provided, an Orange Book product patent. Orange Book listing requires an approved drug product and a patent that meets FDA listing rules. A research-use method patent ordinarily does not create Orange Book-listed exclusivity by itself.[2] What is the FDA and Orange Book status?The claims do not establish FDA approval of Compound VIIa or Compound VIIc. They also do not identify a New Drug Application, biologics license application, approved dosage form or approved indication. The likely regulatory classifications are:
A small-molecule product would ordinarily face an abbreviated new drug application pathway only after an FDA reference product exists and the proposed product satisfies the applicable sameness and bioequivalence requirements. The patent itself does not create a generic-drug pathway. What generic-entry risks exist?Small-molecule generic riskGeneric risk depends on whether Compound VIIa or VIIc has been approved as an active pharmaceutical ingredient and whether the patent is listed against that product. If no approved product exists, there is no conventional ANDA-based entry event tied to this patent. If a matching product later receives approval, a Paragraph IV certification could challenge listed patent claims. Claims 1 and 4 could be relevant to use-based certification only if the approved label encourages the claimed stabilization or fibril-reduction method. Claim 7 would be more likely to affect a diagnostic product or research platform than an oral therapeutic. Skinny-label and induced-infringement issuesA generic applicant could seek a label that omits a patented use. That strategy would be less effective if the approved label, promotional activity or clinical use necessarily directs physicians to practice TTR stabilization or amyloid-fibril reduction. Claims 1 and 4 do not recite a specific disease. That may complicate a skinny-label strategy if the patented method is inseparable from the product’s principal use. The outcome would depend on the approved label and claim construction. Biosimilar riskBiosimilar risk is low on the present record. The patent claims small-molecule-style defined compounds and assay methods, not an antibody, recombinant protein or other biologic. A biosimilar applicant would not ordinarily challenge this patent merely because the reference product affects TTR. What formulation and manufacturing protection exists?No formulation or manufacturing claims appear in the nine claims supplied. The claims do not expressly cover:
That does not prove that the broader patent family lacks such protection. It means that the identified claims provide no direct formulation or manufacturing barrier. A commercial developer should distinguish the method claims from possible follow-on rights covering the selected salt, polymorph, formulation or manufacturing route. Such follow-on patents often control practical launch timing even when the original method patent is weak. Which companies are challenging the patent?The supplied patent claims do not identify a Paragraph IV challenger, inter partes review petitioner, district-court defendant, settlement agreement or licensee. No litigation or licensing conclusion can be drawn from the claims alone. The commercial competitor set for TTR stabilizers includes:
Tafamidis, acoramidis and RNA-silencing products compete clinically but do not create identical patent risks. Stabilizers target the TTR tetramer, while RNA-silencing agents reduce TTR production. Their patent estates therefore differ in claim type, regulatory pathway and manufacturing technology. How strong is the patent estate?Strengths
Vulnerabilities
Overall, the patent appears stronger as a targeted research and assay patent than as a complete commercial product barrier. Its highest value would arise if Compound VIIc is the active or analytical form used in a marketed TTR program and if related family members add composition, formulation or treatment claims. Key Takeaways
FAQsDoes U.S. Patent 10,842,777 claim tafamidis?The supplied claims do not identify tafamidis by name or establish that Compound VIIa or VIIc is tafamidis. Chemical identity must be confirmed from the patent’s structural drawings and specification. Can a diagnostic laboratory infringe claim 7?Potentially. A laboratory method may fall within claim 7 if it uses labeled Compound VIIa, binds it to the T4 pocket, uses a second labeled compound, peptide or protein at an orthogonal TTR surface, and measures distance-dependent energy transfer. Does the patent cover all TTR amyloidosis treatments?No. The supplied claims are limited to methods using Compound VIIa or its defined species. They do not cover unrelated TTR stabilizers, RNA-silencing drugs or antibody therapies. Is a salt of Compound VIIc covered?Yes, claim 3, claim 6 or claim 9 expressly includes a pharmaceutically acceptable salt of Compound VIIc, provided the other claim limitations are satisfied. Can a product avoid the patent by using a different Ra substituent?Possibly, but only if the alternative structure falls outside the full Compound VIIa definition and does not otherwise meet the relevant claim. A different Ra group alone may not avoid infringement if it remains within the claimed genus or if a related patent contains broader composition or method claims. References
More… ↓ |
Drugs Protected by US Patent 10,842,777
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bridgebio Pharma | ATTRUBY | acoramidis hydrochloride | TABLET;ORAL | 216540-001 | Nov 22, 2024 | RX | Yes | Yes | 10,842,777 | ⤷ Start Trial | TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,842,777
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2934514 | ⤷ Start Trial | 301323 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2934514 | ⤷ Start Trial | C20250016 | Finland | ⤷ Start Trial |
| European Patent Office | 2934514 | ⤷ Start Trial | CA 2025 00013 | Denmark | ⤷ Start Trial |
| European Patent Office | 2934514 | ⤷ Start Trial | PA2025512 | Lithuania | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
